Quel est le prix pour Nanjing Leads Biolabs Co Ltd (9887)

Le prix pour Nanjing Leads Biolabs Co Ltd (9887) est $9.26

Quelle est la capitalisation boursière pour Nanjing Leads Biolabs Co Ltd (9887)

La capitalisation boursière pour Nanjing Leads Biolabs Co Ltd (9887) est $1.84B

Nanjing Leads Biolabs Co Ltd (9887) Divisions d'Actions

Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.